+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drug & Gene Delivery Devices Market - Global Forecast 2026-2032- Product Image
Drug & Gene Delivery Devices Market - Global Forecast 2026-2032- Product Image
Sale

Drug & Gene Delivery Devices Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5336343
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drug & Gene Delivery Devices Market is projected to reach USD 2.37 Billion in 2026. It is expected to continue growing at a CAGR of 9.29%, reaching USD 4.05 Billion by 2032.

Drug and gene delivery devices sit at the center of a rapidly evolving therapeutic ecosystem, connecting advanced biologics, precision medicines, vaccines, and cell and gene therapies with patients in clinically controlled, scalable, and user-friendly formats. The category spans autoinjectors, wearable injectors, infusion pumps, inhalation systems, implantable delivery platforms, microneedles, viral vector delivery, non-viral vectors, lipid nanoparticles, electroporation systems, and other enabling technologies that improve dosing accuracy, adherence, stability, and patient access.

Demand is being shaped by the growth of chronic disease management, biologic drug launches, home-based care, specialty pharmaceuticals, and the clinical expansion of gene therapies. Regulatory agencies such as the U.S. FDA and European Medicines Agency continue to emphasize combination-product quality, human factors engineering, device reliability, sterility assurance, and post-market safety, making validated device design and evidence-based delivery performance key differentiators across the drug delivery devices and gene delivery systems landscape.

Transformative Shifts Reshaping Delivery Platforms

The landscape is shifting from hospital-centered administration toward connected, patient-centric, and minimally invasive delivery. Prefilled syringes, autoinjectors, on-body injectors, smart pumps, and digital adherence tools are enabling more therapies to move into outpatient and home-care settings, while biologics with higher viscosities and larger dose volumes are accelerating innovation in wearable and high-force injection systems.

In gene delivery, the industry is moving beyond a reliance on established viral vectors toward optimized adeno-associated virus platforms, lentiviral systems, lipid nanoparticles, polymeric carriers, and targeted non-viral delivery. These shifts are supported by advances in genomic medicine, mRNA technology, payload engineering, and manufacturing analytics, but they also increase the need for scalable production, cold-chain resilience, immunogenicity management, and regulatory-grade characterization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across the drug and gene delivery device lifecycle. In discovery and formulation, AI models help screen excipients, predict nanoparticle behavior, evaluate protein stability, and optimize vector design. In device engineering, machine learning supports simulation-led design, failure-mode analysis, human factors testing, and predictive quality controls that can shorten development cycles when validated against robust experimental data.

AI is also strengthening manufacturing and post-market performance. Computer vision, sensor analytics, and predictive maintenance improve process control for sterile fill-finish, vector production, assembly, and packaging, while real-world data analytics can identify adherence patterns, infusion anomalies, and safety signals. The strongest opportunities are emerging where AI is governed by traceable data, explainable validation, cybersecurity controls, and compliance with evolving FDA, EMA, and international expectations for software, connected devices, and quality management systems.

Key Regional Insights Across Global Markets

Asia-Pacific is advancing as a major region for drug delivery devices and gene delivery technologies due to expanding biologics pipelines, government investment in biotechnology, large patient populations, and rising demand for self-administered therapies. China, Japan, South Korea, India, and Australia are strengthening clinical research, local manufacturing, and regulatory pathways for advanced therapies, while regional cost sensitivity continues to favor scalable, reliable, and value-engineered delivery platforms.

North America remains a leading innovation and commercialization hub, supported by FDA-cleared combination products, advanced biomanufacturing, clinical trial infrastructure, and a large specialty-pharmaceutical ecosystem. Europe benefits from the European Medicines Agency framework, established medtech clusters, strong biosimilar adoption, and advanced therapy medicinal product regulation, while Latin America is advancing through private healthcare expansion, vaccine infrastructure, and gradual adoption of specialty injectable therapies across Brazil, Mexico, and other major healthcare systems.

The Middle East is investing in healthcare modernization, specialty care, medical infrastructure, and localization strategies, particularly in Gulf markets, while Africa presents long-term potential linked to vaccination programs, infectious disease control, and improving cold-chain and primary-care infrastructure. Across all regions, successful market entry depends on regulatory readiness, payer evidence, device usability, temperature-controlled logistics, and partnerships that align innovative delivery technologies with local healthcare delivery models.

Key Group Insights for Strategic Expansion

ASEAN markets are gaining importance as medical tourism, local pharmaceutical production, and regional harmonization efforts improve access to injectable drugs, vaccines, biosimilars, and specialty therapies. The group offers demand for practical, cost-efficient drug delivery devices that can perform reliably in diverse healthcare settings, humid climates, and decentralized care environments.

The GCC is prioritizing healthcare transformation, domestic life sciences investment, and advanced hospital infrastructure, creating opportunities for premium drug delivery devices, connected adherence solutions, and specialty therapy platforms. The European Union remains a regulatory and innovation anchor for combination products and advanced therapy medicinal products, with medical device regulation, pharmacovigilance expectations, data protection rules, and sustainability policy influencing device design, packaging, traceability, and lifecycle management.

BRICS countries combine large patient bases with rising biologics manufacturing capacity and growing public investment in biotechnology, making affordability, technology transfer, local production, and scalable quality systems central to adoption. G7 markets continue to set quality, reimbursement, intellectual property, and clinical-evidence benchmarks for high-value drug and gene delivery platforms, while NATO countries' focus on medical readiness and secure supply chains reinforces demand for resilient manufacturing, stockpiling capabilities, cybersecurity, and dependable injectable and vaccine delivery systems.

Key Country Insights in Drug & Gene Delivery Devices

The United States leads in drug delivery device innovation, combination-product approvals, connected health adoption, and gene therapy commercialization, supported by FDA regulatory pathways, advanced clinical trial networks, and strong specialty pharmaceutical spending. Canada offers a stable regulatory environment, public health system purchasing discipline, and growing biologics adoption, while Mexico is strengthening its role in medtech manufacturing and regional supply chains. Brazil remains Latin America's largest healthcare system, with opportunities tied to biosimilars, vaccines, and injectable therapies that meet public and private payer requirements.

In Europe, the United Kingdom supports life sciences innovation through strong academic and clinical infrastructure, while Germany remains a major medtech and biopharma manufacturing center. France combines advanced hospital networks with public investment in biotechnology, and Italy and Spain contribute established pharmaceutical manufacturing, clinical research, and specialty-care demand. Russia has maintained interest in domestic pharmaceutical production and vaccine platforms, though market access, regulatory navigation, and supply-chain planning require careful risk assessment.

China is scaling biomanufacturing, clinical development, and domestic innovation in biologics and gene delivery, while India is expanding vaccine, biosimilar, and cost-efficient device capabilities. Japan's mature regulatory system and aging population support demand for safe, easy-to-use delivery devices, and South Korea is advancing through biologics manufacturing, digital health, and cell and gene therapy research. Australia provides a strong clinical trial environment, transparent regulation, and demand for high-quality delivery systems across chronic disease and specialty-care applications.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize patient-centric engineering, validated human factors, and lifecycle quality from the earliest stages of device and therapy development. For drug delivery devices, this means designing for dose accuracy, reduced pain, reliable activation, intuitive training, connectivity where clinically useful, and compatibility with high-viscosity biologics. For gene delivery systems, leaders should invest in vector optimization, targeted delivery, scalable analytics, and manufacturing platforms that reduce variability and improve process robustness.

Commercial success will depend on integrated evidence strategies that combine clinical outcomes, usability data, pharmacoeconomic value, and real-world performance. Companies should build regional regulatory intelligence, diversify suppliers for critical components, strengthen cold-chain and sterile manufacturing resilience, and pursue partnerships with biopharma developers, contract development and manufacturing organizations, digital health firms, and healthcare providers to accelerate adoption while maintaining compliance.

Research Methodology and Data Validation

This executive summary is built on a secondary-research framework using publicly available and verifiable sources such as regulatory agency publications, clinical trial registries, peer-reviewed literature, patent databases, healthcare policy documents, pharmacovigilance materials, and international health and trade datasets. Key reference points include FDA and EMA guidance on combination products and advanced therapies, WHO materials on vaccines and access, and recognized public data from organizations such as the World Bank, OECD, and national health agencies.

Insights are synthesized through triangulation across technology trends, regulatory developments, regional healthcare infrastructure, product commercialization patterns, and manufacturing dynamics. The methodology emphasizes data consistency, source credibility, recency, and practical relevance for decision-makers in drug delivery devices, gene delivery technologies, biopharmaceutical manufacturing, medtech investment, and healthcare strategy.

Conclusion: Delivery Innovation as a Competitive Advantage

The drug and gene delivery devices landscape is entering a phase where therapeutic innovation, device usability, digital intelligence, and manufacturing excellence are inseparable. As biologics, mRNA platforms, and cell and gene therapies expand, delivery technologies will determine how effectively advanced medicines reach patients at scale.

Organizations that combine regulatory-grade evidence, patient-centered design, AI-enabled quality systems, resilient supply chains, and region-specific commercialization strategies will be best positioned to create sustainable value. The next competitive advantage will come not only from novel therapies, but from delivery platforms that make those therapies safer, more accessible, more reliable, and more economically sustainable.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Drug & Gene Delivery Devices Market, by Technology
7.1. Introduction
7.2. Hydrogel Based
7.3. Liposomal
7.4. Nanoparticle
7.5. Polymer Based
8. Drug & Gene Delivery Devices Market, by Device Type
8.1. Introduction
8.2. Auto Injector
8.3. Infusion Pump
8.4. Needle Free Injector
8.5. Pen Injector
8.6. Syringe
9. Drug & Gene Delivery Devices Market, by Molecule Type
9.1. Introduction
9.2. Biologic
9.2.1. Monoclonal Antibody
9.2.2. Peptide
9.2.3. Recombinant Protein
9.3. Gene Therapy
9.3.1. Non Viral
9.3.1.1. Lipid Based
9.3.1.2. Polymer Based
9.3.2. Viral Vector
9.3.2.1. Adenoviral
9.3.2.2. Lentiviral
9.3.2.3. Retroviral
9.4. Small Molecule
10. Drug & Gene Delivery Devices Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Healthcare
10.4. Hospitals
10.5. Research Laboratories
11. Drug & Gene Delivery Devices Market, by Application
11.1. Introduction
11.2. Controlled Release
11.3. Smart Delivery
11.4. Sustained Release
11.5. Targeted Delivery
12. Drug & Gene Delivery Devices Market, by Therapeutic Area
12.1. Introduction
12.2. Cardiovascular
12.3. Diabetes
12.4. Infectious Diseases
12.5. Oncology
13. Drug & Gene Delivery Devices Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Drug & Gene Delivery Devices Market, by Group
14.1. NATO
14.2. G7
14.3. BRICS
14.4. European Union
14.5. ASEAN
14.6. GCC
15. Drug & Gene Delivery Devices Market, by Country
15.1. China
15.2. United States
15.3. Japan
15.4. India
15.5. Germany
15.6. United Kingdom
15.7. Australia
15.8. France
15.9. South Korea
15.10. Italy
15.11. Canada
15.12. Russia
15.13. Brazil
15.14. Mexico
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. AptarGroup, Inc.
17.3. Bausch + Lomb Incorporated
17.4. Baxter International Inc.
17.5. Becton, Dickinson and Company
17.6. Camurus AB
17.7. Cook Medical LLC
17.8. Elixir Medical Corporation
17.9. Enable Injections, Inc.
17.10. Gerresheimer AG
17.11. Haselmeier GmbH
17.12. Insulet Corporation
17.13. Medtronic plc
17.14. Nipro Corporation
17.15. Owen Mumford Limited
17.16. Phillips-Medisize, LLC
17.17. Santen Pharmaceutical Co., Ltd.
17.18. SCHOTT Pharma AG & Co. KGaA
17.19. SHL Medical AG
17.20. Spectrum Plastics Group
17.21. Stevanato Group S.p.A.
17.22. Tandem Diabetes Care, Inc.
17.23. Teleflex Incorporated
17.24. Terumo Corporation
17.25. West Pharmaceutical Services, Inc.
17.26. Ypsomed Holding AG
List of Figures
FIGURE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 7. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 15. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2032 (%)
FIGURE 17. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL HYDROGEL BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL HYDROGEL BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL HYDROGEL BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LIPOSOMAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LIPOSOMAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LIPOSOMAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NANOPARTICLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NANOPARTICLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NANOPARTICLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL POLYMER BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL POLYMER BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL POLYMER BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL AUTO INJECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL AUTO INJECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL AUTO INJECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL INFUSION PUMP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL INFUSION PUMP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL INFUSION PUMP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL NEEDLE FREE INJECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL NEEDLE FREE INJECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NEEDLE FREE INJECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PEN INJECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PEN INJECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PEN INJECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SYRINGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SYRINGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SYRINGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL BIOLOGIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL BIOLOGIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL BIOLOGIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL PEPTIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL PEPTIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PEPTIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL RECOMBINANT PROTEIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL NON VIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL NON VIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NON VIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL LIPID BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL LIPID BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL LIPID BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL POLYMER BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL POLYMER BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL POLYMER BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ADENOVIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ADENOVIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ADENOVIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL LENTIVIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL LENTIVIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL LENTIVIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL RETROVIRAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL RETROVIRAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RETROVIRAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL SMALL MOLECULE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL SMALL MOLECULE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL SMALL MOLECULE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL HOME HEALTHCARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOME HEALTHCARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOME HEALTHCARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CONTROLLED RELEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL SMART DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL SMART DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL SMART DELIVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL SUSTAINED RELEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL SUSTAINED RELEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL SUSTAINED RELEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL TARGETED DELIVERY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL TARGETED DELIVERY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL TARGETED DELIVERY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 123. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 125. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 126. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 127. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 128. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 129. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 130. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 131. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 132. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 133. EUROPE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 156. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 158. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 159. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 160. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 161. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 162. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 163. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 164. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 165. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 166. AFRICA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 167. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 178. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 179. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 181. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 182. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 183. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 184. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 185. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 186. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 187. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 188. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 189. NATO DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 190. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 191. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 192. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 193. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 194. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 195. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 196. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 197. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 198. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 200. G7 DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 201. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 203. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 204. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 205. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 206. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 207. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 208. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 209. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 210. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 211. BRICS DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 217. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 218. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 219. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 220. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 221. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 222. EUROPEAN UNION DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 223. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 224. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 225. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 226. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 227. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 228. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 229. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 230. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 231. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 233. ASEAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 234. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 235. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 236. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 237. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 238. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 239. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 240. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 241. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 242. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 243. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 244. GCC DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 245. GLOBAL DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 246. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 248. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 249. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 250. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 251. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 252. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 253. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 254. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 256. CHINA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 257. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 259. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 260. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 261. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 262. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 263. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 264. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 265. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 266. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 267. UNITED STATES DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 268. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 270. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 271. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 272. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 273. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 274. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 275. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 276. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 278. JAPAN DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 279. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 281. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 282. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 283. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 284. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 285. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 286. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 287. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 289. INDIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 290. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 292. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 293. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 294. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 295. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 296. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 297. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 298. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 299. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 300. GERMANY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 301. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 302. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 303. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 310. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 311. UNITED KINGDOM DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 312. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 314. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 315. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 316. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 317. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 318. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 319. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 320. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 322. AUSTRALIA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 323. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 324. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 325. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 326. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 327. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 328. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 329. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 330. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 331. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 332. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 333. FRANCE DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 334. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 336. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 337. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY MOLECULE TYPE, 2017-2032 (USD MILLION)
TABLE 338. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY BIOLOGIC, 2017-2032 (USD MILLION)
TABLE 339. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 340. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY NON VIRAL, 2017-2032 (USD MILLION)
TABLE 341. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY VIRAL VECTOR, 2017-2032 (USD MILLION)
TABLE 342. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 343. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 344. SOUTH KOREA DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY THERAPEUTIC AREA, 2017-2032 (USD MILLION)
TABLE 345. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 346. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 347. ITALY DRUG & GENE DELIVERY DEVICES MARKET SIZE, BY DEVICE TYPE, 2017-2032 (USD MILLION)
TABLE 348. ITALY DRUG & GENE DELIVERY DEVICE

Companies Mentioned

  • Abbott Laboratories
  • AptarGroup, Inc.
  • Bausch + Lomb Incorporated
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Camurus AB
  • Cook Medical LLC
  • Elixir Medical Corporation
  • Enable Injections, Inc.
  • Gerresheimer AG
  • Haselmeier GmbH
  • Insulet Corporation
  • Medtronic plc
  • Nipro Corporation
  • Owen Mumford Limited
  • Phillips-Medisize, LLC
  • Santen Pharmaceutical Co., Ltd.
  • SCHOTT Pharma AG & Co. KGaA
  • SHL Medical AG
  • Spectrum Plastics Group
  • Stevanato Group S.p.A.
  • Tandem Diabetes Care, Inc.
  • Teleflex Incorporated
  • Terumo Corporation
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.37 Billion
Forecasted Market Value ( USD ) by 2032 $ 4.05 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Drug and Gene Delivery Devices - Global Strategic Business Report - Product Image

Drug and Gene Delivery Devices - Global Strategic Business Report

  • Report
  • 278 Pages
  • Global
From
Gene Therapy Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene Delivery Method, Route of Administration, Geographical Regions, Leading Players and Sales Forecast - Product Image

Gene Therapy Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Therapeutic Area, Type of Vector, Type of Therapy, Type of Gene Delivery Method, Route of Administration, Geographical Regions, Leading Players and Sales Forecast

  • Report
  • 972 Pages
  • Global
From
Gene Delivery Technologies Market - Global Forecast 2026-2032 - Product Image

Gene Delivery Technologies Market - Global Forecast 2026-2032

  • Report
  • 188 Pages
  • Global
From
Drug and Gene Delivery Devices Market Report 2026 - Product Image

Drug and Gene Delivery Devices Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Non-Viral Gene Delivery Technologies Market Report 2026 - Product Image

Non-Viral Gene Delivery Technologies Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Market

The Drug and Gene Delivery market within the context of Genomics is a rapidly growing field of research and development. It involves the use of various technologies to deliver drugs and genes to specific cells or tissues in the body. This can be done through a variety of methods, such as viral vectors, liposomes, nanoparticles, and other delivery systems. These technologies are used to treat a variety of diseases, including cancer, cardiovascular diseases, and neurological disorders. The Drug and Gene Delivery market is driven by the increasing demand for personalized medicine, as well as the need for more effective treatments for diseases. Additionally, advances in gene editing technologies have enabled the development of more precise and targeted therapies. Some of the major players in the Drug and Gene Delivery market include Novartis, Merck, Pfizer, Sanofi, and AstraZeneca. Other companies in the market include Amgen, GlaxoSmithKline, Johnson & Johnson, and Bristol-Myers Squibb. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.